局部进展期或交界可切除胰腺导管腺癌患者的预后因素:化疗与放化疗对比
本研究纳入215例交界可切除或局部进展期胰腺导管腺癌患者,分别接受化疗(82例)或同步放化疗(133例)作为一线治疗,分析临床资料与CT影像表现对总生存期和无进展生存期的预测价值。结果显示CT不均匀强化是全人群及两种治疗方式共有的预后因素,CT阳性淋巴结仅与化疗组不良OS相关,CA19-9>1000 U/mL仅与放化疗组不良OS相关。
要点
- CT不均匀强化是全人群(HR 1.95,p<0.001)及化疗组(HR 2.04,p=0.006)、放化疗组(HR 1.73,p=0.006)共有的不良OS预后因素。
- 化疗组与放化疗组中位OS(15.3 vs 16.8个月,p=0.297)和中位PFS(10.0 vs 11.7个月,p=0.321)均无显著差异。
- CT阳性淋巴结仅与化疗组不良OS相关(HR 2.38,p=0.036),CA19-9>1000 U/mL仅与放化疗组不良OS相关(HR 2.38,p=0.001)。
关键影像表现/征象
- CT不均匀强化与全研究人群较短的总生存期相关(HR 1.95,p<0.001)。
- CT上存在阳性淋巴结与化疗组不良总生存期相关(HR 2.38,p=0.036)。
诊断标准与关键数值
- CA19-9>1000 U/mL与全研究人群较短的总生存期相关(HR 1.91,p=0.001)。
- 化疗组中,不均匀强化(HR 2.04,p=0.006)和CT阳性淋巴结(HR 2.38,p=0.036)与不良总生存期相关。
- 放化疗组中,CA19-9>1000 U/mL(HR 2.38,p=0.001)和不均匀强化(HR 1.73,p=0.006)是不良总生存期的独立预测因素。
临床应用与阅片要点
- 阅片时可关注胰腺病灶的强化模式,不均匀强化提示较差的预后。
- 在化疗患者中,CT检出阳性淋巴结提示预后不良。
- 在放化疗患者中,治疗前CA19-9>1000 U/mL提示预后不良。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify common and unique pre-treatment prognostic factors in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), treated with chemotherapy (CTx) or concurrent chemoradiotherapy (CRT).
METHODS: We enrolled 215 patients with BR/LA PDAC, who were treated with either CTx (n = 82) or CRT (n = 133) as a first-line treatment between 2013 and 2016. Clinical data and CT imaging findings for predicting overall survival (OS) and progression-free survival (PFS) were analyzed using Cox regression analysis.
RESULTS: Carbohydrate antigen (CA) 19-9 > 1000 U/mL (hazard ratio [HR] 1.91; p = 0.001) and non-homogeneous enhancement (HR 1.95; p < 0.001) were associated with shorter OS in all study populations. There was no significant difference in median OS (15.3 vs 16.8 months, p = 0.297) and PFS (10.0 vs 11.7 months, p = 0.321) between the CTx and CRT groups. Non-homogeneous enhancement (HR 2.04; p = 0.006) and presence of positive lymph node on CT (HR 2.38; p = 0.036) were associated with poor OS in the CTx group, while CA 19-9 > 1000 U/mL (HR 2.38; p = 0.001) and non-homogeneous enhancement (HR 1.73; p = 0.006) were independent predictors for poor OS in the CRT group.
CONCLUSION: Enhancement pattern on CT was a common prognostic factor for patients with PDAC treated with either CTx or CRT. Presence of positive lymph nodes on CT was a poor prognostic factor for the CTx group only, whereas CA 19-9 > 1000 U/mL was a poor prognostic factor for the CRT group only.
引用
- Kim SS, Lee S, Lee HS, et al. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol (NY). 2020. PMID: 32748250. doi:10.1007/s00261-020-02661-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。